Sionna Therapeutics(NASDAQ) SION

Sionna Therapeutics, Inc. makes new medicines for cystic fibrosis. The company helps patients breathe better by repairing a specific protein. These treatments aim to restore healthy function to the body.

The Science of Better Breathing

• NBD1 Stabilizers: Medicines like SION-719 and SION-451 that target a protein section called nucleotide binding domain 1 to help it work correctly.
• Complementary Modulators: Support drugs like SION-2222 and SION-109 that help stabilizers work more effectively in the body.
• Dual Combinations: Treatment pairings that use two different drugs together to restore normal functions in patients.

Pathways to New Treatments

• Reported data from Phase 1 clinical trials for SION-719 and SION-451 in June 2025.
• Initiated a Phase 1 trial in August 2025 to evaluate SION-451 in drug combinations.
• Completed patient enrollment for a Phase 2a proof-of-concept trial in April 2026.
• Established an agreement in March 2026 to sell up to $250.0 million in stock through an at-the-market program.

What Makes the Approach Different

Sionna focuses on the nucleotide binding domain 1, or NBD1, which is a specific part of the protein that helps move salt and water in the body. By stabilizing this area, the company aims to restore protein function to levels near those seen in healthy individuals.

By the Numbers

• Market capitalization was $2.1 billion according to recent market data.
• Net loss was $56.7 million for the six months ended June 30, 2026.
• Cash, cash equivalents, and marketable securities reached $268.3 million as of June 30, 2026.
• Research and development expenses were $40.8 million for the six-month period ended June 30, 2026.
• Accumulated deficit reached $313.0 million as of June 30, 2026.

The Bottom Line

Sionna has transitioned into a mid-stage clinical company focused on developing proprietary combination therapies for cystic fibrosis. Its strategy centers on targeting specific protein domains to improve upon existing treatment options.